Antonio Cicione1, Francesco Cantiello1, Giuseppe Ucciero1, Andrea Salonia2, Marco Torella3, Marco De Sio4, Riccardo Autorino4, Antonio Carbone5, Martin Romancik6, Roman Tomaskin7, Rocco Damiano1. 1. Department of Urology & Research Doctorate Urology Program, Magna Graecia University, Catanzaro, Italy; 2. Department of Urology, University Vita-Salute San Raffaele, Milano, Italy; 3. Gynaecology Unit, Second University of Naples, Napoli, Italy; 4. Urology Unit, Second University of Naples, Napoli, Italy; 5. Unit of Urology - ICOT, Sapienza University of Rome, Latina, Italy; 6. Department of Urology, St. Cyril and Method University Hospital, Bratislava, Slovakia; 7. Department of Urology, Faculty Hospital of Martin (MFN), Martin, Slovakia.
Abstract
INTRODUCTION: We assess the effectiveness of intravesical instillation of hyaluronic acid (HA) and chondroitin sulphate (CS) as a non-antibiotic treatment option for prophylaxis of recurrent urinary tract infections (UTIs) in female patients. METHODS: This was a retrospective cohort study involving 7 European institutions. We included patients with recurrent UTIs who received intravesical instillations of Ialuril (IBSA International) (50 mL HA 1.6% and CS 2% solution) between January 2010 and March 2012. Medication schedule, length of follow-up, recurrence infection time, number of UTIs/patients/year, patient quality of life, subjective symptoms score, and treatment-emergent side effects were recorded and analyzed. RESULTS: In total, 157 women (mean age: 54.2 ± 4.1 years) were included in the analysis. All patients had at least 12 months follow-up. After 4 weekly and 5 monthly HA-CS bladder instillations, UTI episodes decreased from 4.13 ± 1.14 to 0.44 ± 0.50 (p = 0.01) at 12 months, while recurrent UTI time prolonged from 94.8 ± 25.1 days to 178.4 ± 37.3 days (p = 0.01) at 12 months. An improvement in symptoms and quality of life was achieved. A medium-depth pain after medication instillation was the most reported side effect. Regression model analysis showed significant risk factors in developing new UTI episodes: being more than 50 years old and having more than 4 UTI episodes per year (OR 3.41; CI 95%; 1.51-7.71, p = 0.003 and OR 3.31; CI 95% 1.51-7.22; p = 0.003, respectively). Retrospective design and lack of a control group represent two main limitations of the study. CONCLUSIONS: Restoring glycosaminoglycans bladder layer therapy is a promising non-antibiotic therapy to prevent recurrent UTIs.
INTRODUCTION: We assess the effectiveness of intravesical instillation of hyaluronic acid (HA) and chondroitin sulphate (CS) as a non-antibiotic treatment option for prophylaxis of recurrent urinary tract infections (UTIs) in female patients. METHODS: This was a retrospective cohort study involving 7 European institutions. We included patients with recurrent UTIs who received intravesical instillations of Ialuril (IBSA International) (50 mL HA 1.6% and CS 2% solution) between January 2010 and March 2012. Medication schedule, length of follow-up, recurrence infection time, number of UTIs/patients/year, patient quality of life, subjective symptoms score, and treatment-emergent side effects were recorded and analyzed. RESULTS: In total, 157 women (mean age: 54.2 ± 4.1 years) were included in the analysis. All patients had at least 12 months follow-up. After 4 weekly and 5 monthly HA-CS bladder instillations, UTI episodes decreased from 4.13 ± 1.14 to 0.44 ± 0.50 (p = 0.01) at 12 months, while recurrent UTI time prolonged from 94.8 ± 25.1 days to 178.4 ± 37.3 days (p = 0.01) at 12 months. An improvement in symptoms and quality of life was achieved. A medium-depth pain after medication instillation was the most reported side effect. Regression model analysis showed significant risk factors in developing new UTI episodes: being more than 50 years old and having more than 4 UTI episodes per year (OR 3.41; CI 95%; 1.51-7.71, p = 0.003 and OR 3.31; CI 95% 1.51-7.22; p = 0.003, respectively). Retrospective design and lack of a control group represent two main limitations of the study. CONCLUSIONS: Restoring glycosaminoglycans bladder layer therapy is a promising non-antibiotic therapy to prevent recurrent UTIs.
Authors: C Lowell Parsons; Jeffrey Dell; Edward J Stanford; Michael Bullen; Bruce S Kahn; Tracy Waxell; James A Koziol Journal: Urology Date: 2002-10 Impact factor: 2.649
Authors: Kasper M A Rouschop; Marc Sylva; Gwendoline J D Teske; Inge Hoedemaeker; Steven T Pals; Jan J Weening; Tom van der Poll; Sandrine Florquin Journal: J Immunol Date: 2006-11-15 Impact factor: 5.422
Authors: E Costantini; M Lazzeri; D Pistolesi; M Del Zingaro; E Frumenzio; A Boni; A Pietropaolo; E Fragalà; M Porena Journal: Urol Int Date: 2013-03-13 Impact factor: 2.089
Authors: C A Czaja; W E Stamm; A E Stapleton; P L Roberts; T R Hawn; D Scholes; M Samadpour; S J Hultgren; T M Hooton Journal: J Infect Dis Date: 2009-08-15 Impact factor: 5.226
Authors: Catherine A Mowbray; Syema Shams; Git Chung; Anna Stanton; Phillip Aldridge; Andrejus Suchenko; Robert S Pickard; Ased Sm Ali; Judith Hall Journal: Clin Transl Immunology Date: 2018-06-07
Authors: Paul Loubet; Jérémy Ranfaing; Aurélien Dinh; Catherine Dunyach-Remy; Louis Bernard; Franck Bruyère; Jean-Philippe Lavigne; Albert Sotto Journal: Front Microbiol Date: 2020-07-03 Impact factor: 5.640